Research and Markets: Competitor Analysis: GLP-1 Receptor Agonists Development Pipeline Report 2014

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/wdwv7x/competitor) has announced the addition of the "Competitor Analysis: GLP-1 Receptor Agonists" report to their offering.

The Competitive Intelligence Report Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists as of August 2014 provides a competitor analysis in the development pipeline of novel GLP-1 analogs and GLP-1 receptor agonists and co-agonists for treatment of diabetes and obesity.

In the year 2013, the marketed daily and weekly GLP-1 agonists achieved combined sales of US$ 3,231 mln representing 6.3% of the total diabetes care market. The leading GLP-1 analog Victoza held 69% of the GLP-1 market and is further expanding its predominance in the first half of 2014 with a 72% share of the GLP-1 market which grew to 6.9% of the total diabetes care market.

The increasingly attractive GLP-1 market provides an opportunity of application of new technologies to prolong the half-life of GLP-1 analogs as well as finding co-agonists of GLP-1 receptor with additional receptors, such as insulin, glucagon, GIP, gastrin or GLP-1. In addition, expansion of indications for GLP-1 analogs will contribute to further expand the GLP-1 market.

The report provides a compilation of current active projects in research and development of novel GLP-1 analogs and GLP-1 receptor agonists as well as co-agonists.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

1. Selective GLP-1 Analogs for Metabolic Diseases

  • 2013 Sales of GLP-1 Analogs
  • Short-Acting Injectable GLP-1 Analogs
  • Long-Acting Injectable GLP-1 Analogs
  • Very Long-Acting Injectable GLP-1 Analogs
  • Oral Peptide-Based GLP-1 Analogs
  • Other Non-Injectable Peptide-Based GLP-1 Analogs
  • Oral Small Molecule GLP-1 Receptor Agonists

2. Selective GLP-1 Analogs for Non-Metabolic Diseases

3. Dual Target GLP-1 Analogs

  • GLP-1 and Insulin
  • GLP-1 and Glucagon
  • GLP-1 and GIP
  • GLP-1 and Gastrin/CCKB
  • GLP-1 and GLP-2

4. Corporate GLP-1 Receptor Agonist R&D Pipelines

Companies Mentioned

  • Addex Pharmaceuticals
  • Amylin Pharmaceuticals
  • Arisaph Pharmaceuticals
  • Arisgen
  • Ascendis Pharma (Complex Biosystems)
  • Bio-ker
  • Biocompatibles International
  • ConjuChem
  • Dong-A Pharmaceutical
  • Eli Lilly
  • Emisphere Technologies
  • Faust Pharmaceuticals
  • GlaxoSmithKline
  • Hanmi Pharmaceuticals
  • Ipse
  • Mannkind
  • MDRNA (ex Nastech Pharmaceuticals)
  • Modigene
  • Novo Nordisk
  • OctoPlus
  • Oramed Pharmaceuticals
  • Pfizer
  • Proxima Concepts
  • Roche (& Chugai)
  • Rose Pharmaceuticals (ex Gastrotech)
  • Sanofi-Aventis
  • Teijin
  • Transition Therapeutics
  • TransTech Pharma
  • Unigene

For more information visit http://www.researchandmarkets.com/research/wdwv7x/competitor

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals, Drug Discovery

Sharing

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals, Drug Discovery